{"id":19039,"date":"2022-03-01T16:31:04","date_gmt":"2022-03-01T16:31:04","guid":{"rendered":"https:\/\/zeepedia.com\/?p=19039"},"modified":"2022-03-02T14:24:39","modified_gmt":"2022-03-02T14:24:39","slug":"ninlaro","status":"publish","type":"post","link":"https:\/\/zeepedia.com\/medical\/medicines\/ninlaro\/","title":{"rendered":"NINLARO &#8211; Ixazomib uses, dose and side effects"},"content":{"rendered":"\n<p>2.3 mg, 3 mg, 4 mg&nbsp;hard capsules<br>ixazomib<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What NINLARO is and what it is used for<\/h2>\n\n\n\n<p><strong>What NINLARO is<\/strong><\/p>\n\n\n\n<p>NINLARO is a cancer drug that contains ixazomib, a &#8220;proteasome inhibitor&#8221;.<\/p>\n\n\n\n<p>NINLARO is used to treat a\u00a0bone marrow\u00a0cancer called multiple\u00a0myeloma.\u00a0Its active substance ixazomib acts by blocking the function of\u00a0proteasomes.\u00a0These are structures inside the cell that break down\u00a0proteins\u00a0and are important for cell survival.\u00a0Because myeloma cells produce a lot of\u00a0protein, they can be killed with proteasome inhibitors by blocking the function of proteasomes.<\/p>\n\n\n\n<p><strong>What NINLARO is used for<\/strong><\/p>\n\n\n\n<p>NINLARO is used to treat adults with multiple\u00a0myeloma.\u00a0NINLARO will be given to you together with lenalidomide and <a href=\"https:\/\/zeepedia.com\/medical\/medicines\/toflacort\/\">dexamethasone<\/a>, which are other medicines used to treat multiple\u00a0myeloma.<\/p>\n\n\n\n<p><strong>What multiple&nbsp;myeloma&nbsp;is<\/strong><\/p>\n\n\n\n<p>Multiple\u00a0myeloma\u00a0is a blood cancer that affects a type of cell called a plasma cell.\u00a0A plasma cell is a blood cell that normally produces\u00a0a protein\u00a0to fight\u00a0infection.\u00a0People with multiple\u00a0myeloma\u00a0have cancerous plasma cells, also known as myeloma cells, and they can damage the skeleton.\u00a0The protein\u00a0produced by myeloma cells can damage the kidneys.\u00a0Treatment for multiple\u00a0myeloma\u00a0includes killing myeloma cells and reducing the symptoms of the disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What you need to know before you take NINLARO<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Do not take NINLARO:<\/h2>\n\n\n\n<ul class=\"wp-block-list\"><li>if you are allergic to ixazomib or any of the other ingredients of this medicine (listed in section 6).<\/li><\/ul>\n\n\n\n<p>If you are not sure if any of the above applies to you, talk to your doctor, pharmacist, or nurse before taking NINLARO.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Warnings and cautions<\/h2>\n\n\n\n<p>Talk to your doctor, pharmacist, or nurse before taking NINLARO or during treatment if:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>you have had bleeding in the past<\/li><li>you have persistent nausea, vomiting or diarrhea<\/li><li>you have previously had nerve problems such as&nbsp;tingling or numbness<\/li><li>you have previously had swelling<\/li><li>you have a long-lasting rash or a severe rash with scaly skin and sores in the oral cavity (Stevens \u2011 Johnson syndrome)<\/li><li>you have or have had liver or kidney problems, as your&nbsp;dose&nbsp;may need to be adjusted<\/li><li>you have or have had damage to the smallest blood vessels, so-called thrombotic microangiopathy or thrombotic thrombocytopenic purpura.&nbsp;Tell your doctor if you get tiredness, fever, bruising, bleeding, decreased urination, swelling, confusion, vision loss and seizures.<\/li><\/ul>\n\n\n\n<p>Your doctor will examine you and you will be closely monitored during treatment.&nbsp;Before you start taking NINLARO and during treatment, you will take blood samples to check if you have enough blood cells.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Children and young people<\/h2>\n\n\n\n<p>NINLARO is not recommended for children and adolescents under 18 years of age.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Other medicines and NINLARO<\/h2>\n\n\n\n<p>Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take any other medicines.\u00a0This also applies to any over-the-counter medicines, e.g.\u00a0vitamin\u00a0er or herbal remedies.\u00a0This is because other medicines may affect the way NINLARO works.\u00a0In particular, tell your doctor, pharmacist, or nurse if you are taking any of the following medicines: carbamazepine,\u00a0phenytoin, rifampicin, and St. John&#8217;s\u00a0wort\u00a0(\u00a0<em>Hypericum perforatum<\/em>\u00a0).\u00a0These medicines should be avoided as they may reduce the effect of NINLARO.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Pregnancy and breastfeeding<\/h2>\n\n\n\n<p>NINLARO is not recommended during pregnancy as it may harm the unborn baby.&nbsp;Breast-feeding should be discontinued when taking NINLARO.<\/p>\n\n\n\n<p>Avoid getting pregnant or breastfeeding while being treated with NINLARO.\u00a0If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.<\/p>\n\n\n\n<p>Whether you are a woman or a man, if you are\u00a0fertile, you must use an effective contraceptive during treatment and for 90 days after treatment.\u00a0Women who use hormonal contraceptives should also use barrier contraceptives.\u00a0Tell your doctor immediately if you or your partner becomes pregnant during treatment with NINLARO.<\/p>\n\n\n\n<p>Because NINLARO is given in combination with lenalidomide, you should follow the contraceptive program for lenalidomide as lenalidomide may be harmful to the unborn baby.<\/p>\n\n\n\n<p>See the Lenalidomide and Dexamethasone Package Leaflet for more information on pregnancy and breastfeeding.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Driving and using machines<\/h2>\n\n\n\n<p>NINLARO may affect the ability to drive and use machines.\u00a0You may feel tired and dizzy after taking NINLARO.\u00a0Do not drive or use machines if you experience these\u00a0side effects.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How to take NINLARO<\/h2>\n\n\n\n<p>NINLARO must be prescribed for you by a doctor who has experience in treating multiple\u00a0myeloma.\u00a0Always take this medicine exactly as your doctor or pharmacist has told you.<\/p>\n\n\n\n<p>NINLARO is used with lenalidomide (a medicine that affects the way your immune system works) and dexamethasone (an anti-inflammatory medicine).<\/p>\n\n\n\n<p>NINLARO, lenalidomide, and dexamethasone are taken in 4-week treatment cycles.\u00a0NINLARO is taken once a week (on the same day of the week) for the first 3 weeks of this cycle.<\/p>\n\n\n\n<p>The recommended&nbsp;dose&nbsp;is a 4 mg capsule taken by mouth.<\/p>\n\n\n\n<p>The recommended\u00a0dose\u00a0of lenalidomide is 25 mg taken daily for the first 3 weeks of the cycle.\u00a0The recommended\u00a0dose of\u00a0dexamethasone is 40 mg taken once a week, on the same day for all 4 weeks of the cycle.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td><strong>Dosage schedule: NINLARO with lenalidomide and dexamethasone<\/strong>\u00a0Take the medicine<\/td><\/tr><tr><td><strong>28-day cycle (a 4-week cycle)<\/strong><\/td><\/tr><tr><td><\/td><td><strong>Week 1<\/strong><\/td><td><strong>Week 2<\/strong><\/td><td><strong>Week 3<\/strong><\/td><td><strong>Week 4<\/strong><\/td><\/tr><tr><td><\/td><td>Day 1<\/td><td>Day2 to 7<\/td><td>Day 8<\/td><td>Day9 to 14<\/td><td>Day 15<\/td><td>Day16 to 21<\/td><td>Day 22<\/td><td>Day 23 to 28<\/td><\/tr><tr><td>NINLARO<\/td><td><strong><em>v<\/em><\/strong><\/td><td><\/td><td><strong><em>v<\/em><\/strong><\/td><td><\/td><td><strong><em>v<\/em><\/strong><\/td><td><\/td><td><\/td><td><\/td><\/tr><tr><td>Lenalidomide<\/td><td><strong><em>v<\/em><\/strong><\/td><td><strong><em>v<\/em><\/strong>&nbsp;Daily<\/td><td><strong><em>v<\/em><\/strong><\/td><td><strong><em>v<\/em><\/strong>&nbsp;Daily<\/td><td><strong><em>v<\/em><\/strong><\/td><td><strong><em>v<\/em><\/strong>&nbsp;Daily<\/td><td><\/td><td><\/td><\/tr><tr><td>Dexamethasone<\/td><td><strong><em>v<\/em><\/strong><\/td><td><\/td><td><strong><em>v<\/em><\/strong><\/td><td><\/td><td><strong><em>v<\/em><\/strong><\/td><td><\/td><td><strong><em>v<\/em><\/strong><\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>You should read the package leaflets for these other medicines for more information on their use and effects.<\/p>\n\n\n\n<p>If you have liver or kidney problems, your doctor may prescribe NINLARO capsules containing 3 mg.\u00a0If you have\u00a0any side effects, your doctor may prescribe NINLARO capsules containing 3 mg or 2.3 mg.\u00a0Your doctor may also adjust the\u00a0doses\u00a0of your other medicines.<\/p>\n\n\n\n<p><strong>How and when to take NINLARO<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Take NINLARO at least one hour before or at least two hours after a meal.<\/li><li>Swallow the capsule whole with water.&nbsp;The capsule must not be crushed, chewed or opened.<\/li><li>Do not allow the contents of the capsule to come into contact with your skin.&nbsp;If the powder accidentally comes in contact with your skin, wash thoroughly with soap and water.&nbsp;If a canister breaks, avoid spreading dust during cleaning.<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">If you take more NINLARO than you should<\/h2>\n\n\n\n<p>Accidental overdose can cause serious\u00a0side effects.\u00a0If you take more NINLARO than you should, talk to a doctor immediately or seek medical advice immediately.\u00a0Take the medicine pack with you.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">If you forget to take NINLARO<\/h2>\n\n\n\n<p>If you miss a\u00a0dose\u00a0or a\u00a0dose\u00a0delay, take\u00a0one as long as there are more than 3 days or 72 hours left until the next\u00a0scheduled\u00a0dose.\u00a0Do not take a missed\u00a0dose\u00a0if there are less than 3 days or 72 hours left until the next scheduled\u00a0dose.<\/p>\n\n\n\n<p>If you vomit after taking a\u00a0dose, do not take an extra\u00a0dose.\u00a0Take the next\u00a0dose\u00a0as usual when it&#8217;s time.<\/p>\n\n\n\n<p>If you have any further questions on the use of this product, ask your doctor or pharmacist.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The length of treatment with NINLARO<\/h2>\n\n\n\n<p>You should continue treatment until your doctor tells you to stop.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Possible side effects<\/h2>\n\n\n\n<p>Like all medicines, this medicine can cause\u00a0side effects, although not everybody gets them.<\/p>\n\n\n\n<p><strong>Tell your doctor or pharmacist immediately if you get any of the following very common and serious&nbsp;side effects&nbsp;that may affect more than 1 in 10 people:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>low&nbsp;platelet count&nbsp;(&nbsp;thrombocytopenia&nbsp;) which can increase the risk of nosebleeds and you can more easily get bruises<\/li><li>nausea, vomiting and diarrhea<\/li><li>numbness, stinging or burning sensation in the hands or feet (&nbsp;peripheral&nbsp;neuropathy&nbsp;)<\/li><li>swelling of the legs or feet (peripheral&nbsp;edema&nbsp;)<\/li><li>skin rashes that can itch and occur in a few areas of the body as well as all over the body.<\/li><li>cough, chest pain or nasal congestion (&nbsp;bronchitis&nbsp;).<\/li><\/ul>\n\n\n\n<p><strong>Also, tell your doctor immediately if you get any of the following rare\u00a0side effects\u00a0that may affect up to 1 in 1,000 people:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>severe skin rash such as red or purple bumps (Sweet&#8217;s syndrome) or rash with skin flakes and sores in the oral cavity (Stevens \u2011 Johnson syndrome)<\/li><li>muscle weakness, loss of sensation in the toes and feet or difficulty moving the legs (transverse&nbsp;myelitis&nbsp;)<\/li><li>vision changes, altered state of consciousness or seizures (posterior reversible&nbsp;encephalopathy&nbsp;syndrome)<\/li><li>cancer cells that die quickly and can cause dizziness, decreased urination, confusion, vomiting, nausea, swelling, shortness of breath or heart rhythm disorders (tumor light syndrome)<\/li><li>rare blood disease caused by blood clots and can cause fatigue, fever, bruising, bleeding e.g.&nbsp;nosebleeds, decreased urination, swelling, confusion, loss of vision and seizures (thrombotic microangiopathy, thrombotic thrombocytopenic purpura).<\/li><\/ul>\n\n\n\n<p><strong>Other possible&nbsp;side effects&nbsp;are<\/strong><\/p>\n\n\n\n<p>If any of the&nbsp;side effects&nbsp;gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.<\/p>\n\n\n\n<p><strong>Very common&nbsp;side effects&nbsp;that may affect more than 1 in 10&nbsp;&nbsp;<\/strong><strong>people<\/strong>&nbsp;:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>constipation<\/li><li>back pain<\/li><li>cold symptoms (upper respiratory tract infection)<\/li><li>fatigue or weakness<\/li><li>decreased&nbsp;white blood cell count&nbsp;called&nbsp;neutrophils&nbsp;(&nbsp;neutropenia&nbsp;), which may increase the risk of&nbsp;infection<\/li><li>no desire to eat (decreased appetite)<\/li><li>irregular heartbeat (&nbsp;arrhythmia&nbsp;)<\/li><li>vision problems, including blurred vision, dry eyes and red eyes (&nbsp;conjunctivitis&nbsp;).<\/li><\/ul>\n\n\n\n<p><strong>Common&nbsp;side effects&nbsp;that may affect up to 1 in 10 people:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>reactivation of chickenpox virus (&nbsp;shingles&nbsp;) that can cause rash and pain (&nbsp;herpes&nbsp;zoster)<\/li><li>decreased&nbsp;blood pressure&nbsp;(&nbsp;hypotension&nbsp;)<\/li><li>shortness of breath or persistent cough or wheezing (&nbsp;heart failure&nbsp;)<\/li><li>yellowing of the eyes and skin (jaundice which may be a symptom of hepatic impairment)<\/li><li>low potassium levels in the blood (&nbsp;hypokalaemia&nbsp;).<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">How to store NINLARO<\/h2>\n\n\n\n<p>Keep this medicine out of the sight and reach of children.<\/p>\n\n\n\n<p>Do not use this medicine after the expiry date which is stated on the blister pack, the wallet pack, and the carton after EXP.\u00a0The expiration date is the last day of the specified month.<\/p>\n\n\n\n<p>Do not store above 30 \u00b0 C.&nbsp;Do not freeze.<\/p>\n\n\n\n<p>Store in the original package.&nbsp;Moisture sensitive.<\/p>\n\n\n\n<p>Do not remove the capsules from the package until you are taking a\u00a0dose.<\/p>\n\n\n\n<p>Do not use this medicine if you notice damaged or signs that the medicine pack has been opened.<\/p>\n\n\n\n<p>Medicines should not be disposed of via wastewater or household waste.&nbsp;Ask your pharmacist how to dispose of medicines no longer required.&nbsp;These measures will help to protect the environment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Contents of the package and other information<\/h2>\n\n\n\n<h2 class=\"wp-block-heading\">Content declaration<\/h2>\n\n\n\n<p>NINLARO 2.3 mg hard capsule:<\/p>\n\n\n\n<p>The active substance is ixazomib.&nbsp;Each capsule contains 2.3 mg of ixazomib (as 3.3 mg of ixazomib citrate).<\/p>\n\n\n\n<p>Other ingredients are:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>In the capsule: microcrystalline cellulose, magnesium stearate and talc.<\/li><li>The capsule shell contains: gelatin, titanium dioxide (E171) and red iron oxide (E172).<\/li><li>The printing ink contains: shellac, propylene glycol, potassium hydroxide and black iron oxide (E172).<\/li><\/ul>\n\n\n\n<p>NINLARO 3 mg hard capsule:<\/p>\n\n\n\n<p>The active substance is ixazomib.&nbsp;Each capsule contains 3 mg of ixazomib (as 4.3 mg of ixazomib citrate).<\/p>\n\n\n\n<p>Other ingredients are:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>In the capsule: microcrystalline cellulose, magnesium stearate and talc.<\/li><li>The shell of the capsule contains: gelatin, titanium dioxide (E171) and black iron oxide (E172).<\/li><li>The printing ink contains: shellac, propylene glycol, potassium hydroxide and black iron oxide (E172).<\/li><\/ul>\n\n\n\n<p>NINLARO 4 mg hard capsule:<\/p>\n\n\n\n<p>The active substance is ixazomib.&nbsp;Each capsule contains 4 mg of ixazomib (as 5.7 mg of ixazomib citrate).<\/p>\n\n\n\n<p>Other ingredients are:<\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>In the capsule: microcrystalline cellulose, magnesium stearate and talc.<\/li><li>The shell of the capsule contains: gelatin, titanium dioxide (E171), yellow iron oxide (E172) and red iron oxide (E172).<\/li><li>The printing ink contains: shellac, propylene glycol, potassium hydroxide and black iron oxide (E172).<\/li><\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">What the medicine looks like and contents of the pack<\/h2>\n\n\n\n<p>NINLARO 2.3 mg hard capsule: Light pink, size 4, marked with &#8220;Takeda&#8221; on the upper part and &#8220;2.3 mg&#8221; on the lower part of the housing with black color.<\/p>\n\n\n\n<p>NINLARO 3 mg hard capsule: Light gray, size 4, marked with &#8220;Takeda&#8221; on the upper part and &#8220;3 mg&#8221; on the lower part of the housing with black color.<\/p>\n\n\n\n<p>NINLARO 4 mg hard capsule: Light orange, size 3, marked with &#8220;Takeda&#8221; on the upper part and &#8220;4 mg&#8221; on the lower part of the housing with black color.<\/p>\n\n\n\n<p>Each pack contains 3 hard capsules (three individual cartons, each containing a blister card in a wallet pack. Each blister contains one capsule).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Marketing Authorisation Holder<\/h2>\n\n\n\n<p>Takeda Pharma A \/ S<\/p>\n\n\n\n<p>Delta Park 45<\/p>\n\n\n\n<p>2665 Vallensbaek Strand<\/p>\n\n\n\n<p>Denmark<\/p>\n\n\n\n<p><strong>Manufacturer<\/strong><\/p>\n\n\n\n<p>Takeda Ireland Limited<\/p>\n\n\n\n<p>Grange Castle Business Park<\/p>\n\n\n\n<p>Dublin 22<\/p>\n\n\n\n<p>D22 XR57<\/p>\n\n\n\n<p>Ireland<\/p>\n\n\n\n<p>Takeda GmbH<\/p>\n\n\n\n<p>Takeda (Work Singing)<\/p>\n\n\n\n<p>Robert Bosch Stra\u00dfe 8<\/p>\n\n\n\n<p>78224 Singen<\/p>\n\n\n\n<p>Germany<\/p>\n\n\n\n<p>Contact the representative of the marketing authorization holder to find out more about this medicine:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td><strong>Belgium \/ Belgique \/ Belgien<\/strong>Takeda BelgiumTel: +32 2 464 06 11takeda-belgium@takeda.com<\/td><td><strong>Lithuania<\/strong>Takeda, UABTel: +370 521 09 070lt-info@takeda.com<\/td><\/tr><tr><td><strong>Bulgaria<\/strong>Takade BulgariaTel .: + 359 2 958 27 36;<\/td><td><strong>Luxembourg \/ Luxemburg<\/strong>Takeda BelgiumTel: +32 2 464 06 11takeda-belgium@takeda.com<\/td><\/tr><tr><td><strong>Czech Republic<\/strong>Takeda PharmaceuticalsCzech Republic sroTel: +420 234722722<\/td><td><strong>Hungary<\/strong>Takeda Pharma Kft.Tel: +361 2707030<\/td><\/tr><tr><td><strong>Denmark<\/strong>Takeda Pharma A \/ STel: +45 46 77 11 11<\/td><td><strong>Malta<\/strong>Drugsales LtdTel: +356 21419070safety@drugsalesltd.com<\/td><\/tr><tr><td><strong>Germany<\/strong>Takeda GmbHTel: +49 0800 825 3325medinfo@takeda.de<\/td><td><strong>The Netherlands<\/strong>Takeda Nederland bvTel: +31 20 203 5492medinfoEMEA@takeda.com<\/td><\/tr><tr><td><strong>Eesti<\/strong>Takeda Pharma ASTel: +372 6177 669<\/td><td><strong>Norway<\/strong>Takeda ASTel: +47 6676 3030infonorge@takeda.com<\/td><\/tr><tr><td><strong>Greece<\/strong>TAKEDA \u0395\u039b\u039b\u0391\u03a3 \u0391.\u0395:\u0397\u03bb: +30 210 6387800gr.info@takeda.com<\/td><td><strong>Austria<\/strong>Takeda Pharma Ges.mbHTel: +43 (0) 800-20 80 50<\/td><\/tr><tr><td><strong>Spain<\/strong>Takeda Pharmac\u00e9utica Espa\u00f1a SATel: +34 917 14 99 00spain@takeda.com<\/td><td><strong>Poland<\/strong>Takeda Pharma sp.&nbsp;z ooTel .: + 48 22 608 13 00<\/td><\/tr><tr><td><strong>France<\/strong>Takeda FranceTel: +33 1 46 25 16 16<\/td><td><strong>Portugal<\/strong>Takeda Pharmaceuticals Portugal, Lda.Tel: + 351 21 120 1457<\/td><\/tr><tr><td><strong>Croatia<\/strong>Takeda Pharmaceuticals Croatia dooTel: +385 1 377 88 96<\/td><td><strong>Romania<\/strong>Takeda Pharmaceuticals SRLTel: +40 21 335 03 91<\/td><\/tr><tr><td><strong>Ireland<\/strong>Takeda Products Ireland LimitedTel: +353 (0) 1 6420021<\/td><td><strong>Slovenia<\/strong>Takeda Pharmaceuticals pharmaceutical companyTel: + 386 (0) 59 082 480<\/td><\/tr><tr><td><strong>Iceland<\/strong>Vistor hf.Phone: +354 535 7000vistor@vistor.is<\/td><td><strong>Slovak Republic<\/strong>Takeda Pharmaceuticals Slovakia sroTel: +421 (2) 20 602 600<\/td><\/tr><tr><td><strong>Italy<\/strong>Takeda Italia SpATel: +39 06 502601<\/td><td><strong>Finland \/ Finland<\/strong>Takeda OyPuh \/ Tel: +358 20 746 5000<\/td><\/tr><tr><td><strong>.\u03a0\u03c1\u03bf\u03c2<\/strong>A. POTAMITIS MEDICARE LTDT\u03b7\u03bb: +357 22583333info@potamitismedicare.com<\/td><td><strong>Sweden<\/strong>Takeda Pharma ABTel: +46 8 731 28 00infosweden@takeda.com<\/td><\/tr><tr><td><strong>Latvia<\/strong>Takeda Latvia SIATel: +371 67840082<\/td><td><strong>United Kingdom (Northern Ireland)<\/strong>Takeda UK LtdTel: +44 (0) 2830 640 902medinfoemea@takeda.com<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>NINLARO is a cancer drug that contains ixazomib, a &#8220;proteasome inhibitor&#8221;.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"cybocfi_hide_featured_image":"","footnotes":""},"categories":[2200,15581],"tags":[18998,19003,18994,18997,18999,19002,18995,19000,18996,19001],"class_list":["post-19039","post","type-post","status-publish","format-standard","hentry","category-medicines","category-n","tag-benefits-of-ixazomib","tag-benefits-of-ninlaro","tag-ixazomib","tag-ixazomib-side-effects","tag-ninlaro","tag-ninlaro-side-effects","tag-what-is-ixazomib","tag-what-is-ninlaro","tag-what-ixazomib-is-used-for","tag-what-ninlaro-is-used-for"],"_links":{"self":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/19039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/comments?post=19039"}],"version-history":[{"count":4,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/19039\/revisions"}],"predecessor-version":[{"id":19095,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/posts\/19039\/revisions\/19095"}],"wp:attachment":[{"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/media?parent=19039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/categories?post=19039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zeepedia.com\/medical\/wp-json\/wp\/v2\/tags?post=19039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}